

Switching from Concerta XL™ (methylphenidate) modified release tablets to Delmosart™ prolonged-release tablets

Information for Patients and Carers:

- Concerta XL™ and Delmosart™ prolonged-release tablets contain the same active ingredient which is called methylphenidate.
- The methylphenidate in both Concerta XL™ and Delmosart™ prolonged-release tablets is released into the body over an extended period of time and this is known as modified-release or prolonged-release.
- Both medicines are used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children and adults.

Why is my brand of medicine changing?

- The NHS is constantly looking for ways to improve quality of care and value for money from the services it provides.
- Health services across South East London have agreed a decision to change from Concerta XL™ to Delmosart™ prolonged-release tablets.
- The decision has been made as both Concerta XL™ and Delmosart™ prolonged-release tablets have been shown to be very similar and any differences are unlikely to cause problems with ADHD symptom control.

What changes can I expect from my new medicine?

- The main difference you will notice is the change in the brand name (Delmosart™ prolonged-release tablets instead of Concerta XL™).
- Your tablets will also look different, however, the active ingredient inside, methylphenidate, is the same.
- The proportion of methylphenidate released over time is similar for both Concerta XL™ and Delmosart™ prolonged-release tablets, therefore, there are no expected major differences between the two medicines.
- There should be no change in dose or any other aspect of your treatment unless your doctor has informed you otherwise.

How the new medicine packaging looks:



Alternative Brand of Methylphenidate:

- Delmosart™ prolonged-release tablets will usually be the prescribers' first or second choice brand of modified-release methylphenidate.
- If there is a particular reason why Delmosart™ prolonged-release tablets are not suitable for a patient then Xenidate™ prolonged-release tablets may be considered.
- Xenidate™ also contains methylphenidate in a prolonged-release formulation, similar to Delmosart™ prolonged-release tablets, and has been approved as an appropriate alternative to Concerta XL™.

Advice, support and information for patients and carers:

- Contact your local mental health team or ADHD service for advice. Please inform your doctor if you notice any change in your ADHD symptom control after starting your new medicine.

References:

- London Medicines Information Service, Extended-release methylphenidate – a review of the pharmacokinetic profiles of available products, 2018; <https://www.sps.nhs.uk/articles/extended-release-methylphenidate-a-review-of-the-pharmacokinetic-profiles-of-available-preparations/> [Date last accessed: 22/07/2020]
- Changing from Concerta® to Xenidate® Information for carers and patients. South West London Clinical Commissioning Groups and South West London and St George's Mental Health NHS Trust. May 2018